Search

Your search keyword '"Brunetti, Antonio"' showing total 6 results
Start Over Author "Brunetti, Antonio" Publisher edizioni minerva medica
6 results on '"Brunetti, Antonio"'

1. Italian National Registry of Alopecia Areata: an epidemiological study of 699 Italian patients

Author

PIRACCINI, Bianca Maria, primary, RAPPARINI, Luca, additional, QUADRELLI, Federico, additional, ALESSANDRINI, Aurora, additional, BRUNI, Francesca, additional, CEDIRIAN, Stephano, additional, PAMPALONI, Francesca, additional, MARCELLI, Emanuela, additional, BORTOLANI, Barbara, additional, GIAMPIERI, Enrico, additional, GALLO, Giuseppe, additional, TORRELLI, Francesca, additional, SCIAMARRELLI, Nadia, additional, QUAGLINO, Pietro, additional, TOMASINI, Carlo, additional, BARRUSCOTTI, Stefania, additional, AMBROGIO, Francesca, additional, FOTI, Caterina, additional, PICCIALLO, Michele, additional, CARO, Gemma, additional, ROSSI, Alfredo, additional, PELLACANI, Giovanni, additional, ALA, Lorenzo, additional, ACRI, Maria Cristina, additional, DILUVIO, Laura, additional, MATTEINI, Enrico, additional, BIANCHI, Luca, additional, ARGENZIANO, Giuseppe, additional, BABINO, Graziella, additional, FULGIONE, Elisabetta, additional, GNESOTTO, Laura, additional, SECHI, Andrea, additional, NALDI, Luigi, additional, TASSONE, Francesco, additional, PERIS, Ketty, additional, CALDAROLA, Giacomo, additional, CAPOSIENA CARO, Raffaele Dante, additional, BAZZACCO, Giulia, additional, ZALAUDEK, Iris, additional, VASTARELLA, Maria, additional, CANTELLI, Mariateresa, additional, PATRÌ, Angela, additional, DALL’OGLIO, Federica, additional, LACARRUBBA, Francesco, additional, MICALI, Giuseppe, additional, FRAGHÌ, Alessandro, additional, BOCCALETTI, Valeria, additional, MARZANO, Angelo Valerio, additional, BARBARESCHI, Mauro, additional, SILVIO, Martina, additional, VAGNOZZI, Emanuele, additional, FARGNOLI, Maria Concetta, additional, CAPONIO, Chiara, additional, ATZORI, Laura, additional, SANNA, Silvia, additional, ANEDDA, Jasmine, additional, FELICIANI, Claudio, additional, DE FELICI DEL GIUDICE, Maria Beatrice, additional, SCANDAGLI, Ilaria, additional, PRIGNANO, Francesca, additional, RONGIOLETTI, Franco, additional, PODO BRUNETTI, Antonio, additional, BIGOTTO, Gianmarco D., additional, OFFIDANI, Anna Maria, additional, SIMONETTI, Oriana, additional, LEMBO, Serena, additional, RAIMONDO, Annunziata, additional, BALESTRI, Riccardo, additional, IORIS, Tommaso, additional, GISONDI, Paolo, additional, BELLINATO, Francesco, additional, TROVATO, Emanuele, additional, CINOTTI, Elisa, additional, PAPINI, Manuela, additional, CICOLETTI, Michela, additional, CORAZZA, Monica, additional, and STARACE, Michela, additional

Published
2024
Full Text
View/download PDF

4. Proinflammatory profile of visceral adipose tissue and oxidative stress in severe obese patients carrying the variant rs4612666 C of NLRP3 gene

Author

PERRI, Anna, primary, LOFARO, Danilo, additional, LA RUSSA, Antonella, additional, LUPINACCI, Simona, additional, TOTEDA, Giuseppina, additional, CURTI, Achiropita, additional, URSO, Antonino, additional, BONOFIGLIO, Renzo, additional, LA RUSSA, Daniele, additional, PELLEGRINO, Daniela, additional, BRUNETTI, Antonio, additional, and GRECO, Emanuela, additional

Published
2021
Full Text
View/download PDF

5. The role of intravenous immunoglobulin in autoimmune diseases with dermatological implications.

Author

Podo Brunetti A, DE Rosa C, Bottino V, and Rongioletti F

Abstract

Intravenous immunoglobulin (IVIG) therapy has emerged as a promising treatment option for various dermatological autoimmune diseases due to its immunomodulatory potential and low incidence of severe side effects. Despite its widespread use, the mechanism of action of IVIG in treating autoimmune diseases remains a topic of debate. IVIG is derived from the plasma fractionation of a large pool of donors, primarily consisting of the IgG isotype. Its main mechanisms of action involve neutralizing circulating autoantibodies via the F(ab')2 portion, inhibiting complement-mediated tissue destruction, and reducing the half-life of circulating autoantibodies through the Fc portion. This paper explores the growing utilization of IVIG as an off-label therapy in dermatological autoimmune or immune-mediated diseases, including autoimmune bullous disease (AIBS), dermatomyositis (DM), lupus erythematosus (LE), systemic sclerosis, scleromyxedema, Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), pyoderma gangrenosum (PG), and necrobiotic xanthogranuloma (NXG). In this context, the sole large prospective, randomized trial was the 2022 ProDERM study, which demonstrate efficacy of IVIG in improving cutaneous manifestations among 95 DM patients compared to the placebo group. Moreover, although considered off-label, the use of IVIG is regarded as the first-line therapy for patients with scleromyxedema. As a first line of therapy, IVIg is only approved for Kawasaki Disease (KD) in the setting of vasculitis. The treatment in all other indications is mostly considered as adjuvant therapy only after failure of immunosuppressive therapy or in the presence of contraindications.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results